Article Correctness Is Author's Responsibility: A rapid alternative to standard safety tests for lentiviral vectors

A new, publicly available test to assess the safety of cell therapy products altered by lentivirus generates results within a few hours, potentially hastening the pace at which viral immunotherapies move into clinical trial. Current assays required by the US Food and Drug Administration take about six weeks to complete. The rapid test, which does not have a significant risk of false positives, is also a fraction of the cost of the standard approach.
Posted in Uncategorized